JP5608091B2 - 抗メソセリン抗体およびその使用 - Google Patents

抗メソセリン抗体およびその使用 Download PDF

Info

Publication number
JP5608091B2
JP5608091B2 JP2010535269A JP2010535269A JP5608091B2 JP 5608091 B2 JP5608091 B2 JP 5608091B2 JP 2010535269 A JP2010535269 A JP 2010535269A JP 2010535269 A JP2010535269 A JP 2010535269A JP 5608091 B2 JP5608091 B2 JP 5608091B2
Authority
JP
Japan
Prior art keywords
antibody
seq
mesothelin
dna
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010535269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504372A (ja
Inventor
アントイェ・カーネルト
デイビッド・ライト
ダグ・シュナイダー
レナート・パリー
昇 里澤
タラ・レネー・ヘイトネル・ハンセン
シュテファン・シュタイトル
ウルリケ・シューベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2011504372A publication Critical patent/JP2011504372A/ja
Application granted granted Critical
Publication of JP5608091B2 publication Critical patent/JP5608091B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010535269A 2007-11-26 2008-11-19 抗メソセリン抗体およびその使用 Expired - Fee Related JP5608091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US437807P 2007-11-26 2007-11-26
US61/004,378 2007-11-26
PCT/EP2008/009756 WO2009068204A1 (en) 2007-11-26 2008-11-19 Anti-mesothelin antibodies and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014137893A Division JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2011504372A JP2011504372A (ja) 2011-02-10
JP5608091B2 true JP5608091B2 (ja) 2014-10-15

Family

ID=40351874

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010535269A Expired - Fee Related JP5608091B2 (ja) 2007-11-26 2008-11-19 抗メソセリン抗体およびその使用
JP2014137893A Pending JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用
JP2018038254A Active JP6717869B2 (ja) 2007-11-26 2018-03-05 抗メソセリン抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014137893A Pending JP2014221064A (ja) 2007-11-26 2014-07-03 抗メソセリン抗体およびその使用
JP2018038254A Active JP6717869B2 (ja) 2007-11-26 2018-03-05 抗メソセリン抗体およびその使用

Country Status (30)

Country Link
US (3) US9023351B2 (cg-RX-API-DMAC7.html)
EP (3) EP3103814A1 (cg-RX-API-DMAC7.html)
JP (3) JP5608091B2 (cg-RX-API-DMAC7.html)
KR (1) KR101559599B1 (cg-RX-API-DMAC7.html)
CN (2) CN104151429B (cg-RX-API-DMAC7.html)
AU (1) AU2008329221B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819909B8 (cg-RX-API-DMAC7.html)
CA (1) CA2706529C (cg-RX-API-DMAC7.html)
CO (1) CO6280409A2 (cg-RX-API-DMAC7.html)
CR (1) CR11456A (cg-RX-API-DMAC7.html)
CU (1) CU23833A3 (cg-RX-API-DMAC7.html)
CY (1) CY1117437T1 (cg-RX-API-DMAC7.html)
DK (1) DK2215121T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2010000150A (cg-RX-API-DMAC7.html)
EC (1) ECSP10010191A (cg-RX-API-DMAC7.html)
ES (1) ES2569513T3 (cg-RX-API-DMAC7.html)
GT (1) GT201000148A (cg-RX-API-DMAC7.html)
HN (1) HN2010001062A (cg-RX-API-DMAC7.html)
HR (1) HRP20160485T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027358T2 (cg-RX-API-DMAC7.html)
IL (1) IL205681A0 (cg-RX-API-DMAC7.html)
MA (1) MA31862B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010005603A (cg-RX-API-DMAC7.html)
MY (1) MY157164A (cg-RX-API-DMAC7.html)
NZ (1) NZ585551A (cg-RX-API-DMAC7.html)
PL (1) PL2215121T3 (cg-RX-API-DMAC7.html)
SI (1) SI2215121T1 (cg-RX-API-DMAC7.html)
TN (1) TN2010000234A1 (cg-RX-API-DMAC7.html)
UA (1) UA106036C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009068204A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221064A (ja) * 2007-11-26 2014-11-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268970B2 (en) * 2007-10-01 2012-09-18 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
TWI589589B (zh) * 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
EP2686020B1 (en) 2011-03-17 2017-02-22 The University of Birmingham Re-directed immunotherapy
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP2014515753A (ja) 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
EP2900695B1 (en) * 2012-09-27 2018-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
CN103819559B (zh) * 2013-12-10 2016-02-24 中国科学院武汉病毒研究所 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
IL255697B2 (en) 2015-05-18 2023-11-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
BR112017027702A2 (pt) * 2015-06-30 2018-08-28 Henlius Biotech Co Ltd anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
WO2017032293A1 (zh) * 2015-08-21 2017-03-02 科济生物医药（上海）有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
KR101782487B1 (ko) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
JP6859498B2 (ja) * 2016-02-15 2021-04-14 地方独立行政法人神奈川県立病院機構 膜型ムチン様タンパク質の認識とその医療応用
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
TW201806972A (zh) 2016-05-27 2018-03-01 美商艾伯維生物醫療股份有限公司 雙特異性結合蛋白
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
CA3027302A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
AU2017306267A1 (en) 2016-08-01 2019-02-14 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
CN109715668A (zh) 2016-08-02 2019-05-03 T细胞受体治疗公司 用于使用融合蛋白进行tcr重编程的组合物和方法
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP6339283B1 (ja) 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
MX2020006666A (es) * 2017-12-24 2020-08-31 Noile Immune Biotech Inc Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19.
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
MA52712A (fr) 2018-04-27 2021-03-31 Biogen Ma Inc Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
EP3820898B1 (en) 2018-07-12 2025-09-03 invoX Pharma Limited Antibody molecules that bind cd137 and ox40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
WO2020047501A1 (en) 2018-08-30 2020-03-05 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN113226472B (zh) 2018-12-17 2025-01-28 雷维托普有限公司 双免疫细胞衔接物
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CN113574072B (zh) * 2019-03-14 2023-12-12 莫佛塞斯公司 靶向C5aR的抗体
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
US20220267437A1 (en) * 2019-07-29 2022-08-25 Fred Hutchinson Cancer Research Center Methods and compositions for inducing notch signaling in tumor microenvironments
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN116063527A (zh) * 2021-09-30 2023-05-05 南京北恒生物科技有限公司 靶向间皮素的抗体及其用途
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
IL320482A (en) 2022-10-25 2025-06-01 Peptomyc S L Combination therapy for cancer treatment
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116019939A (zh) * 2022-11-24 2023-04-28 华中科技大学同济医学院附属协和医院 靶向msln的分子探针以及用途
WO2024119065A2 (en) * 2022-12-02 2024-06-06 Jecho Laboratories, Inc. Anti-mesothelin bispecific antibodies and methods of use
AU2024260837A1 (en) 2023-04-25 2025-10-16 Arsenal Biosciences, Inc. Novel receptors for transcription regulation
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202513088A (zh) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｍｅｋ抑制劑的組合療法
AU2024285758A1 (en) 2023-06-07 2025-12-18 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
CN117659133B (zh) * 2023-12-06 2024-09-20 南京鼓楼医院 间皮素靶向结合蛋白、其编码核酸以及用途
CN117843793B (zh) * 2024-03-07 2024-07-09 深圳真实生物医药科技有限公司 抗间皮素抗体、抗原结合片段及其用途
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE254931T1 (de) * 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
AU760120B2 (en) * 1997-12-01 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
AU3007200A (en) * 1999-02-26 2000-09-14 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
US20090047211A1 (en) * 2005-05-12 2009-02-19 The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
ME02059B (me) 2005-05-18 2015-05-20 Morphosys Ag Protutijela protiv gm-csf i njihova upotreba
WO2006130458A2 (en) * 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to cd20 and uses thereof
US8268970B2 (en) * 2007-10-01 2012-09-18 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
EP3103814A1 (en) * 2007-11-26 2016-12-14 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014221064A (ja) * 2007-11-26 2014-11-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 抗メソセリン抗体およびその使用

Also Published As

Publication number Publication date
HK1200856A1 (en) 2015-08-14
WO2009068204A1 (en) 2009-06-04
EP2215121A1 (en) 2010-08-11
US20180258181A1 (en) 2018-09-13
ES2569513T3 (es) 2016-05-11
US20110027268A1 (en) 2011-02-03
CN101952319B (zh) 2015-04-15
EP2634196A1 (en) 2013-09-04
CU23833A3 (es) 2012-10-15
JP2018102311A (ja) 2018-07-05
HUE027358T2 (en) 2016-09-28
HN2010001062A (es) 2013-10-07
MA31862B1 (fr) 2010-11-01
CY1117437T1 (el) 2017-04-26
CR11456A (es) 2010-11-12
EP2215121B1 (en) 2016-02-10
JP2011504372A (ja) 2011-02-10
TN2010000234A1 (en) 2011-11-11
CO6280409A2 (es) 2011-05-20
JP2014221064A (ja) 2014-11-27
SI2215121T1 (sl) 2016-06-30
US20150259433A1 (en) 2015-09-17
PL2215121T3 (pl) 2016-07-29
BRPI0819909A2 (pt) 2017-12-19
CN104151429A (zh) 2014-11-19
CA2706529A1 (en) 2009-06-04
HK1148541A1 (en) 2011-09-09
CN101952319A (zh) 2011-01-19
IL205681A0 (en) 2010-11-30
HRP20160485T1 (hr) 2016-06-03
AU2008329221A1 (en) 2009-06-04
DK2215121T3 (en) 2016-05-02
DOP2010000150A (es) 2010-09-15
BRPI0819909B1 (pt) 2021-04-20
MY157164A (en) 2016-05-13
MX2010005603A (es) 2010-08-02
UA106036C2 (uk) 2014-07-25
KR101559599B1 (ko) 2015-10-12
GT201000148A (es) 2014-04-03
AU2008329221B2 (en) 2013-11-07
ECSP10010191A (es) 2010-07-30
BRPI0819909B8 (pt) 2021-05-25
CA2706529C (en) 2016-10-25
KR20100097660A (ko) 2010-09-03
EP3103814A1 (en) 2016-12-14
NZ585551A (en) 2012-06-29
CN104151429B (zh) 2018-07-10
JP6717869B2 (ja) 2020-07-08
US9023351B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
JP5608091B2 (ja) 抗メソセリン抗体およびその使用
AU2016233495B2 (en) Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
CN107236043B (zh) 在体内具有抗肿瘤活性的抗人trop-2抗体
JP4869074B2 (ja) 抗体
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2020515251A (ja) Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
US9676846B2 (en) Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2024500512A (ja) 抗ｂ７－ｈ３抗体およびその使用
RU2534890C2 (ru) Антитела против mst1r и их применение
HK1200856B (en) Anti-mesothelin antibodies and uses therefor
HK1148541B (en) Anti-mesothelin antibodies and uses therefor
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110825

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140829

R150 Certificate of patent or registration of utility model

Ref document number: 5608091

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees